$300 Million Fund Launched for Growth Stage Startups in Healthtech
This initiative aligns with the significant 207% increase in healthtech funding in 2024, which rose from $233 million to $716 million. Notably, Healthtech funding has seen substantial growth, increasing by 207% in 2024 alone, with funding figures rising from $233 million to $716 million during that period. In fact, AI funding alone accounted for $168 billion, representing 60% of the total funding in the region.
HealthKois has announced the launch of a $300 million fund aimed at supporting growth stage startups within the healthtech and life sciences sectors. This new initiative is managed by the leadership team of HealthQuad, a recognized player in the field, which was founded in 2016.
Focus on Healthtech and Life Sciences
The newly launched fund by HealthKois is specifically targeting startups that are in the growth stage of their development, with a particular emphasis on healthtech and life sciences. This strategic focus aligns with the increasing investment trends observed in these sectors. Notably, Healthtech funding has seen substantial growth, increasing by 207% in 2024 alone, with funding figures rising from $233 million to $716 million during that period.
HealthQuad's previous endeavor, HealthQuad Fund II, closed at $162 million, setting a precedent for significant investment in the evolving healthtech landscape. The overall healthtech funding since 2014 has accumulated to $7 billion, reflecting the growing interest and potential in this sector.
Context of Broader Startup Funding Trends
The launch of this substantial fund comes amid broader trends in startup funding, both within India and globally. Indian startups have cumulatively raised over $150 billion through approximately 10,500 deals, showcasing the vibrant and dynamic nature of the Indian startup ecosystem.
These trends are mirrored in North America, where startup funding saw a 46% increase in 2025, with $280 billion invested in U.S. and Canadian startups. This surge in funding is largely driven by advancements and interest in artificial intelligence, which captured a significant portion of funding. In fact, AI funding alone accounted for $168 billion, representing 60% of the total funding in the region.
Investment in AI and Early-Stage Companies
The influence of artificial intelligence on funding trends cannot be overstated. AI has become a focal point for investors, contributing to a significant portion of the $67 billion invested in the fourth quarter of 2025. Despite a 16% reduction in deal count year-over-year, the financial commitment to AI has remained robust, indicating sustained confidence in its potential.
Moreover, early-stage companies have also benefited from this investment boom, with $69 billion allocated to support their growth in 2025. This reflects a continued interest in nurturing nascent technologies and business models that could drive future innovation and market shifts.
Yearly Funding Fluctuations and Future Outlook
Analyzing yearly fluctuations, 2025 saw a total of $20.4 billion in startup funding, while 2024 experienced a 9% increase from the previous year, marking a progressive trend in capital infusion for startups. The fourth quarter of 2025 alone reported 1,300 seed financings, highlighting ongoing investor interest in early-stage opportunities.
The launch of the $300 million fund by HealthKois is poised to make a significant impact in this evolving landscape, channeling capital into growth stage startups and driving further advancements in healthtech and life sciences. As global funding trends continue to evolve, the focus on healthtech and AI will likely remain strong, fostering innovation and development in these key areas.